Objective There are currently no targeted therapies against lung tumors with oncogenic K-ras mutations that are found in 25% to ?40% of lung cancers and are characterized by their resistance to epidermal growth factor receptor inhibitors. 106 cells per well in 12-well plates in full media for 24 hours and then serum-starved BMS-345541 HCl them (0.5% FBS) for 24 hours before treatment. Cells were treated with sPLA2IIa inhibitor (20 or 40 were performed to determine the time of maximal initial increase in phosphorylation of NF-test was performed for 2-group comparisons, and the analysis of variance test was performed when comparing 3 or more groups. No multiple comparison was conducted. StatView version 5.0 was used for all statistical BMS-345541 HCl analysis (SAS Institute, Inc, Cary, NC). RESULTS sPLA2IIa Expressed in K-ras Mutant Lung Cancer Cells Group IIa sPLA2 expression varies in K-ras mutant lung cancer cells. SW1573 and H2009 express more sPLA2IIa messenger RNA (mRNA) compared with H358 and A549 cells (Physique 1, and expression. Expression varies with SW1573 and H2009 cells expressing more sPLA2IIa compared with H358 and A549 cells. Messenger RNA was evaluated … Cell Survival in K-ras Mutant Lung Cancer Cells Depends on sPLA2IIa Expression sPLA2IIa inhibition led to concentration-dependent apoptosis and cell death in all K-ras mutant lung cancer cells (Physique 2). Cells with higher baseline sPLA2IIa were more susceptible to cell death with sPLA2IIa inhibition. Early apoptosis detected by annexin V staining after 8 hours of sPLA2IIa inhibition was increased in SW1573 and H2009 cells compared with H358 and A549 cells (Physique 2, A). The MTT assay confirmed concentration- dependent cell death after 24 hours of sPLA2IIa inhibition, again with increased vulnerability in cells with higher sPLA2IIa expression (Physique 2, expression inhibition promotes concentration-dependent apoptosis and cell death in lung cancer cell lines, and cytotoxicity of sPLA2IIa inhibition parallels the level of sPLA2IIa expression. SW1573 and H2009 … sPLA2IIa Inhibition in K-ras Mutants Decreases NF-inhibition attenuates nuclear factor kappa-b activity in all cell lines, with a variable effect on extracellular signal-regulated kinase 1/2 activity. NF-express increasing … DISCUSSION This is usually the first study to specifically explore the role of sPLA2IIa in K-ras mutant lung cancer. Consistent with our hypothesis, sPLA2IIa is usually a cytotoxic target in K-ras mutant lung cancer cells. Our obtaining that in vitro sensitivity to sPLA2IIa inhibition correlates with baseline sPLA2IIa expression, regardless of p53 mutation status, suggests that sPLA2IIa expression may predict response to sPLA2IIa inhibition. Analysis of sPLA2IIa expression in human lung tumors revealed some trends that we did not anticipate. Expression increases with cancer stage in K-ras mutant tumors, but it does not necessarily increase with stage of nonCsmall cell lung cancers overall. In addition, we found a trend of relatively high expression in squamous cell tumors, another subset of lung tumors that presently lacks targeted therapy. These findings are intriguing. Not only do they suggest that sPLA2IIa may be a more sensitive biomarker for a subset of tumors, but small molecule inhibitors to sPLA2IIa have already been trialed for inflammatory disease, 11 thus underscoring the possibility for rapid translational study in lung cancer. Although sPLA2 inhibition significantly attenuated NF-W activity in all lung cancer cell lines tested, cells with mutant p53 had a less robust decrease in NF-W activity. Other investigators have exhibited a relationship between mutant p53 and increased baseline NF-W activity.12,13 Our data corroborate this observation and further advance our understanding of the relationship between BMS-345541 HCl sPLA2IIa and NF- B by demonstrating that sPLA2IIa inhibition has Rabbit Polyclonal to PAR4 a more moderate effect on the activity of NF-B in cancer cells where baseline activity is high. Additional studies are needed to determine whether this observation has implications for the effect of sPLA2IIa inhibition on downstream NF-W targets such as metastasis-associated adhesion molecules and expression of inducible growth factors.5,14C17 An interesting and unexpected finding from our tumor.